CC
VRTX icon

Centiva Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Centiva Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,000
Closed -$1.21M – 2185
2024
Q4 		$1.21M Sell
3,000
-1,000
-25% -$464K 0.02% 485
2024
Q3 		$1.86M Hold
4,000
– – 0.04% 492
2024
Q2 		$1.87M Hold
4,000
– – 0.03% 456
2024
Q1 		$1.67M Sell
4,000
-7,300
-65% -$3.09M 0.04% 404
2023
Q4 		$4.6M Buy
11,300
+6,300
+126% +$2.33M 0.11% 175
2023
Q3 		$1.74M Buy
+5,000
New +$1.75M 0.04% 433
2023
Q1 		– Sell
-6,000
Closed -$1.73M – 1875
2022
Q4 		$1.73M Hold
6,000
– – 0.05% 400
2022
Q3 		$1.74M Sell
6,000
-3,000
-33% -$863K 0.03% 402
2022
Q2 		$2.54M Sell
9,000
-8,600
-49% -$2.3M 0.06% 296
2022
Q1 		$4.59M Buy
17,600
+12,600
+252% +$2.99M 0.09% 191
2021
Q4 		$1.1M Buy
+5,000
New +$972K 0.02% 581
2021
Q3 		– Sell
-15,000
Closed -$3.02M – 1636
2021
Q2 		$3.02M Buy
+15,000
New +$3.14M 0.07% 221
2020
Q4 		– Sell
-4,300
Closed -$1.17M – 1123
2020
Q3 		$1.17M Hold
4,300
– – 0.08% 177
2020
Q2 		$1.25M Sell
4,300
-9,100
-68% -$2.47M 0.08% 146
2020
Q1 		$3.19M Buy
13,400
+1,300
+11% +$298K 0.14% 99
2019
Q4 		$2.65M Sell
12,100
-400
-3% -$81K 0.13% 153
2019
Q3 		$2.12M Buy
12,500
+10,800
+635% +$1.91M 0.13% 162
2019
Q2 		$311K Sell
1,700
-9,500
-85% -$1.66M 0.02% 298
2019
Q1 		$2.06M Buy
+11,200
New +$2.07M 0.14% 109

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Centiva Capital's VRTX Position: Q2 2026 in Review

Centiva Capital sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 2,147 shares — an estimated $959K sold.

Centiva Capital first reported a position in VRTX in Q1 2019 and held it in 22 quarters. The position peaked at $3.68M in Q2 2023. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Centiva Capital reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Centiva Capital sold 2,147 Vertex Pharmaceuticals shares in Q2 2026, an estimated $959K.
  • Centiva Capital first reported a position in Vertex Pharmaceuticals in Q1 2019 and held it in 22 quarters.
  • Centiva Capital's Vertex Pharmaceuticals position peaked at $3.68M in Q2 2023.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.